Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Diatos announces the successful completion of Phase I trial for DTS-201, a novel doxorubicin prodrug

Paris, France – October 22, 2007 -- Diatos SA, an international biopharmaceutical company focusing on the research, development and commercialization of targeted anti-cancer drugs, today announced the successful completion of a clinical Phase I trial of its anti-cancer compound, DTS-201, at the American Association of Cancer Research (AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics) meeting in San Francisco, USA. DTS-201 was shown to be well tolerated and evidence of clinical efficacy was observed.

DTS-201 is a novel doxorubicin prodrug developed for the targeted treatment of several solid cancers, including chemo-resistant tumors. DTS-201 uses the Tumor Selective Prodrug (TSP) technology which causes the product to be activated by enzymes specifically expressed by the tumor whilst ignoring healthy cells.

The purpose of the DTS-201 clinical Phase I study was to assess the product’s Maximum Tolerated Dose (MTD), safety profile and pharmacokinetic profile in patients with advanced or metastatic solid tumors. Results from this trial will be presented at the AACR conference in a poster entitled “Results of a first in man phase I study assessing the safety and pharmacokinetics of a one hour intravenous infusion of DTS-201 every 3 weeks in patients with advanced or metastatic solid tumors. (abstract # 776)”.

From the trial, researchers concluded that:

§ DTS-201 was well tolerated by twenty-five cancer patients treated with doses of up to 400 mg/m2 every three weeks

§ Evidence of clinical efficacy was observed: More than 40% of patients had clinical benefit, nine patients with chemo-resistant tumors showed disease stabilisation for at least 4 treatment cycles and one patient showed partial response

§ DTS-201 was safe and well tolerated at cumulative doses of up to 2400 mg/m2 (Doxorubicin equivalent dose is approximately 1300 mg/m2)

§ The main dose limiting toxicity is reversable neutropenia (hematological) of short duration

§ Non-hematological toxicity adverse events were mild to moderate and no drug related cardiac toxicity was observed

§ Clinical data provide first proof of concept in man for the Tumor Selective Prodrug (TSP) technology

§ The recommended dose for clinical Phase II trials is 400 mg/m2

The high level of safety and evidence of clinical efficacy observed during this clinical Phase I trial warrants further assessment of the product in multiple clinical Phase II studies.

President and CEO of Diatos John Tchelingerian, Ph.D, remarked: “This clinical Phase I study with DTS-201 provides us with initial human proof of concept of our Tumor Selective Prodrug technology. The expected initiation of multiple clinical Phase II studies for DTS-201 in the near future demonstrates the potential of our DTS-201 product and the Tumor Selective Prodrug platform technology.”


Notes to Editors:

About DTS-201

DTS-201 is a prodrug designed to preferentially deliver doxorubicin to tumors as opposed to normal tissues. Doxorubicin is a chemotherapy drug widely used to treat a variety of solid tumours and blood cancers. Systemic administration of doxorubicin causes serious, dose-limiting, adverse side effects.

DTS-201 is stable in blood due to the inactivation of doxorubicin by the coupling of a tetrapeptidic sequence which prevents cellular uptake. DTS-201 is cleavable by some specific peptidases present in the tumor environment such as CD10 and Thimet Oligopeptidase (TOP) which are specifically overproduced and released by tumor cells. They produce two intermediate metabolites Ala-Leu-Dox and Leu-Dox which enter stromal and tumor cells and convert DTS-201 into free doxorubicin.

Preclinical studies have demonstrated that DTS-201 was less toxic in animal models than free doxorubicin and significantly more effective in a wide panel of human tumor xenograft models.

DTS-201 was initially d

Publisher Contact Information:

Diatos SA
+33 (0)1 53 80 93 80

Company profile of Diatos SA
Past press releases of Diatos SA.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Dec 21€50.0MKnowledge management
Dec 20€16.0MSemiconductors
Dec 17€18.0MOther Computers & Electronics
Dec 17€5.2MBiotechnology
Dec 17€17.0MBusiness applications
Dec 15€17.0ME-Commerce
Dec 4€3.3MNanotechnology

For information on Europe's most extensive database on technology funding click here!


Press Releases

Sep 30
tetavi raises $6 million to help more companies bring 3d holograms ...

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Mar 31
the fit allocates chf 100'000 to comppair technologies

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.